Trade-Ideas LLC identified

AstraZeneca

(

AZN

) as a pre-market mover with heavy volume candidate. In addition to specific proprietary factors, Trade-Ideas identified AstraZeneca as such a stock due to the following factors:

  • AZN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $184.2 million.
  • AZN traded 1.2 million shares today in the pre-market hours as of 9:17 AM, representing 18.9% of its average daily volume.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in AZN with the Ticky from Trade-Ideas. See the FREE profile for AZN NOW at Trade-Ideas

More details on AZN:

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of respiratory, inflammation, autoimmune, cardiovascular, metabolic, oncology, infection, neuroscience, and gastrointestinal diseases worldwide. The stock currently has a dividend yield of 4.7%. AZN has a PE ratio of 13. Currently there is 1 analyst that rates AstraZeneca a buy, no analysts rate it a sell, and 4 rate it a hold.

The average volume for AstraZeneca has been 4.0 million shares per day over the past 30 days. AstraZeneca has a market cap of $74.1 billion and is part of the health care sector and drugs industry. Shares are down 17.9% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates AstraZeneca as a

hold

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and notable return on equity. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and a generally disappointing performance in the stock itself.

Highlights from the ratings report include:

  • ASTRAZENECA PLC has improved earnings per share by 18.2% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. This trend suggests that the performance of the business is improving. During the past fiscal year, ASTRAZENECA PLC increased its bottom line by earning $1.12 versus $0.49 in the prior year. This year, the market expects an improvement in earnings ($1.98 versus $1.12).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Pharmaceuticals industry. The net income increased by 17.4% when compared to the same quarter one year prior, going from $550.00 million to $646.00 million.
  • The gross profit margin for ASTRAZENECA PLC is currently very high, coming in at 93.10%. Regardless of AZN's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 10.47% trails the industry average.
  • AZN has underperformed the S&P 500 Index, declining 13.35% from its price level of one year ago. Turning toward the future, the fact that the stock has come down in price over the past year should not necessarily be interpreted as a negative; it could be one of the factors that may help make the stock attractive down the road. Right now, however, we believe that it is too soon to buy.
  • The debt-to-equity ratio of 1.11 is relatively high when compared with the industry average, suggesting a need for better debt level management.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.